Nimbus Lakshmi, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Nimbus Lakshmi, Inc. - overview
Established
2010
Location
Boston, MA, US
Primary Industry
Biotechnology
About
Based in the US, Nimbus Lakshmi, Inc. , a subsidiary of Nimbus Discovery, Inc. , (Nimbus Therapeutics, LLC) operates as a biotechnology company specializing in biopharmaceuticals and related discoveries. In February 2023, the firm was acquired by Takeda Pharmaceutical from Nimbus Discovery, Inc.
for USD 4 billion. The company’s research and development pipeline includes NDI-034858 (now known as TAK-279), which is in phase 3 study as of February 2023, for the treatment of psoriasis as well as multiple other immune-mediated diseases such as inflammatory bowel disease, psoriatic arthritis, and systemic lupus erythematosus.
Current Investors
Takeda Pharmaceutical
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals
Total Amount Raised
Subscriber access only
Nimbus Lakshmi, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LP Direct | Completed | Nimbus Lakshmi, Inc. | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.